Utama › Kanser Paru-paru Bukan Sel Kecil › Louisiana
Kajian klinikal Kanser Paru-paru Bukan Sel Kecil di Louisiana
26 kajian untuk Kanser Paru-paru Bukan Sel Kecil sedang mencari peserta di lokasi di Louisiana.
Bandar di Louisiana
Teks kajian rasmi (Bahasa Inggeris)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Christus Saint Frances Cabrini Hospital, Alexandria
- LSU Health Baton Rouge-North Clinic, Baton Rouge
- Our Lady of the Lake Physician Group, Baton Rouge
- dan 11 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT04267848Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Pontchartrain Cancer Center - Covington Office, Covington
- Pontchartrain Cancer Center - Hammond Office, Hammond
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06472245Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- University Medical Center New Orleans, New Orleans
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT06498635A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Mary Bird Perkins Cancer Center, Baton Rouge
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07144280A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- LSU Health Baton Rouge North Clinic ( Site 4003), Baton Rouge
- Our Lady of the Lake Physician Group-Medical Oncology ( Site 0080), Baton Rouge
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06312137Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Pontchartrain Cancer Center, Covington
- Pontchartrain Cancer Center, Hammond
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT07222566Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Mary Bird Perkins Cancer Center, Baton Rouge
- Ochsner Health Ochsner Cancer Center - Baton Rouge, Baton Rouge
- Ochsner Clinic Foundation, New Orleans
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06890598Pan-tumor MRD Study
- Pontchartrain Cancer Center, Covington
- Christus Health Highlands, Shreveport
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06605404A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Louisiana State University Health Sciences Shreveport, Shreveport
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT06875310Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
- Our Lady of the Lake Physician's Group, Baton Rouge
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT06745882A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Mary Bird Perkins Cancer Center, Baton Rouge
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 21 Sep 2026 · NCT07629960A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Baton Rouge
- Research Site, Shreveport
- Research Site, Shreveport
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Covington
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Sep 2026 · NCT06767514Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Local Institution - 007-994-A, Covington
- Pontchartrain Cancer Center - Covington Office, Covington
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT04613596ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Tulane Cancer Center, New Orleans
- Christus Highland/ Boniol, Shreveport
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT05059444A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Mary Bird Perkins Cancer Center, Baton Rouge
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06119581A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
- LSU Health Sciences Center School of Medicine, New Orleans
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT07361562A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Local Institution - 2116, New Orleans
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 27 Mei 2026 · NCT03093116Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
- Tulane Cancer Center, New Orleans
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Mei 2026 · NCT07154706A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
- Ochsner Health, Jefferson
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Mei 2026 · NCT07094204Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Mary Bird Perkins Cancer Center, Baton Rouge
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Mei 2026 · NCT05379985Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Ochsner LSU Health Monroe Medical Center, Monroe
- LSU Health Sciences Center at Shreveport, Shreveport
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Mac 2026 · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, New Orleans
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
- Ochsner/MD Anderson Cancer Center, New Orleans
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Okt 2025 · NCT06228326Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
- University Medical Center - New Orleans, New Orleans
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 10 Okt 2025 · NCT06784193Utilizing Long-read Sequencing to Investigate the EGFR Landscape of EGFR Positive Lung Cancer Patients
- Our Lady of the Lake Regional Medical Center, Baton Rouge
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 18 hingga 100 · Wanita · Dikemas kini 20 Mac 2025 · NCT06659458Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.